- Investing Ideas
- Global Pharmaceuticals & Biotech Top Growth Stocks
Global Pharmaceuticals & Biotech Top Growth Stocks
Results
64
64 companies
Axsome Therapeutics
Market Cap: US$11.3b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$215.69
7D
-0.04%
1Y
93.8%
Madrigal Pharmaceuticals
Market Cap: US$12.1b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$524.37
7D
-2.0%
1Y
38.2%
TG Therapeutics
Market Cap: US$7.0b
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
TGTX
US$50.26
7D
0.7%
1Y
80.0%
Beijing Luzhu Biotechnology
Market Cap: HK$2.6b
A biotechnology company, develops human vaccines and therapeutic biologics to prevent and control infectious diseases, and to treat cancer and autoimmune diseases in Mainland China.
2480
HK$13.03
7D
0.2%
1Y
-50.6%
Oscotec
Market Cap: ₩1.5t
Operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses.
A039200
₩38,100.00
7D
-1.8%
1Y
15.6%
Camurus
Market Cap: SEK 37.3b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMX
SEK 631.00
7D
1.3%
1Y
-6.7%
Insmed
Market Cap: US$28.0b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$128.46
7D
-3.1%
1Y
1.0%
HansBiomed
Market Cap: ₩271.8b
Engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies.
A042520
₩19,060.00
7D
-16.2%
1Y
146.6%
Guangzhou Innogen Pharmaceutical Group
Market Cap: HK$1.9b
Engages in the development of drug engaged in the research, development and commercialization of pharmaceutical products.
2591
HK$4.24
7D
-40.3%
1Y
-91.9%
MedinCell
Market Cap: €878.4m
Engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France.
MEDCL
€24.88
7D
0.5%
1Y
40.0%
Bonesupport Holding
Market Cap: SEK 14.7b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEX
SEK 226.20
7D
0%
1Y
-21.6%
Kuros Biosciences
Market Cap: CHF 863.3m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURN
CHF 22.60
7D
-1.7%
1Y
-17.6%
Praxis Precision Medicines
Market Cap: US$10.5b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
PRAX
US$369.84
7D
-0.2%
1Y
725.6%
AnaptysBio
Market Cap: US$1.8b
A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
ANAB
US$58.99
7D
1.9%
1Y
198.1%
Ardelyx
Market Cap: US$1.0b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$3.92
7D
-0.5%
1Y
-33.1%
Ionis Pharmaceuticals
Market Cap: US$9.9b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$59.62
7D
5.5%
1Y
39.3%
WuXi XDC Cayman
Market Cap: HK$86.2b
An investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.
2268
HK$68.05
7D
6.5%
1Y
18.0%
Cutia Therapeutics
Market Cap: HK$784.9m
An investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong.
2487
HK$2.16
7D
-4.8%
1Y
-76.6%
Amylyx Pharmaceuticals
Market Cap: US$2.4b
A clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
AMLX
US$35.11
7D
48.6%
1Y
349.0%
Corcept Therapeutics
Market Cap: US$12.7b
A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
CORT
US$118.10
7D
5.6%
1Y
68.3%
Zevra Therapeutics
Market Cap: US$684.7m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$11.57
7D
2.0%
1Y
28.5%
Cellectar Biosciences
Market Cap: US$20.6m
A clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States.
CLRB
US$2.59
7D
-0.4%
1Y
-41.3%
Capricor Therapeutics
Market Cap: US$412.2m
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$7.08
7D
69.0%
1Y
-1.3%
Abeona Therapeutics
Market Cap: US$352.3m
A commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
ABEO
US$6.16
7D
-17.4%
1Y
-12.0%
Ocumension Therapeutics
Market Cap: HK$4.2b
Engages in the research, discovery, development, and commercialization of ophthalmic therapies in China.
1477
HK$5.21
7D
-5.2%
1Y
-54.3%
DBV Technologies
Market Cap: €752.8m
A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.
DBV
€2.54
7D
4.3%
1Y
48.1%
Pharma Mar
Market Cap: €1.4b
A biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally.
PHM
€82.10
7D
0.06%
1Y
2.6%
CG Oncology
Market Cap: US$6.8b
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CGON
US$76.29
7D
-1.0%
1Y
198.5%
Grace Therapeutics
Market Cap: US$44.7m
Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
GRCE
US$2.13
7D
1.4%
1Y
-34.9%
Kiniksa Pharmaceuticals International
Market Cap: US$6.2b
A biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
KNSA
US$79.49
7D
1.7%
1Y
139.4%
Arcutis Biotherapeutics
Market Cap: US$3.2b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$26.54
7D
1.2%
1Y
68.3%
PharmaResearch
Market Cap: ₩4.1t
Operates as a biopharmaceutical company primarily in South Korea.
A214450
₩391,000.00
7D
-4.2%
1Y
-40.1%
Oxford Biomedica
Market Cap: UK£595.5m
A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
OXB
UK£5.03
7D
2.1%
1Y
0.2%
Belite Bio
Market Cap: US$6.4b
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States.
BLTE
US$162.57
7D
-8.5%
1Y
163.0%
SIGA Technologies
Market Cap: US$210.5m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$2.99
7D
3.8%
1Y
-65.9%
NewAmsterdam Pharma
Market Cap: US$3.2b
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
NAMS
US$27.25
7D
-1.3%
1Y
11.5%